Results 181 to 190 of about 32,807 (224)

Medication discontinuation in the era of elexacaftor/tezacaftor/ivacaftor: an Australian survey and qualitative interview. [PDF]

Intern Med J
Corbett M, Saini B, Dunn A, Visser S, Jo H, Yozghatlian V, Bell J, Sivam S.   +7 more
europepmc   +1 more source

Triple combination cystic fibrosis transmembrane receptor modulator effects on glycaemia and insulin kinetics in cystic fibrosis with and without diabetes. [PDF]

Intern Med J
Chen YW, Prasad R, Middleton PG, Holmes-Walker DJ.   +3 more
europepmc   +1 more source

Use of Sedation During Non-Invasive Ventilation in Intensive Care Unit: A Systematic Review and Meta-Analysis. [PDF]

J Pers Med
Iacovazzo C, de Siena AU, Kotfis K, Buonanno P, Nappi S, Merola R, Vargas M, Servillo G, Pandharipande PP, Marra A.   +9 more
europepmc   +1 more source

Hydroxypyruvate Reductase 1 and Plastidial Glycolate/Glycerate Transporter 1 Connect Photorespiration With Plant Immunity

Plant, Cell &Environment, Volume 49, Issue 9, Page 6554-6557, September 2026.
Xiaotong Jiang, Sheng Yang He, Jianping Hu   +2 more
wiley   +1 more source

Organelle-centered resistosome signaling in plant immunity. [PDF]

Plant Commun
Wang Q, Yang Y, Zhang L, Chang M.
europepmc   +1 more source

CFTR modulators exert subset-specific phenotype remodeling on circulating neutrophils in cystic fibrosis. [PDF]

Immunohorizons
Chable de la Héronnière F, Dhôte T, de Oliveira Formiga R, Regard L, Saraceni-Tasso G, Andrieu M, Many S, Da Silva J, Pène F, Martin C, Ladjemi MZ, Burgel PR, Witko-Sarsat V.   +12 more
europepmc   +1 more source

Eti Karini Pengabdian Masyarakat

Eti, Karini
core   +1 more source

Remodelling of cystic fibrosis respiratory microbiota in response to extended elexacaftor-tezacaftor-ivacaftor therapy. [PDF]

Microbiome
Gavillet H, Hatfield LR, Hardman M, Marsh R, Einarsson GG, Thornton CS, Parkins MD, Duckers J, Bomberger JM, Hilliam Y, Lee SE, Lord RW, Jones A, Horsley A, Daniels TWV, Teneback CC, Rivett DW, van der Gast C.   +17 more
europepmc   +1 more source

Effect of elexacaftor-tezacaftor-ivacaftor therapy on systemic inflammation in people with cystic fibrosis. [PDF]

J Bras Pneumol
Meyer VMC, Aranha Netto N, Palmeira P, Athanazio RA, Silva-Filho LVRFD.   +4 more
europepmc   +1 more source

One year follow-up of physical activity and health-related quality of life in youth with Cystic Fibrosis in the modulator era. [PDF]

Sci Rep
Kinaupenne M, Vandekerckhove I, Van Biervliet S, Schaballie H, Vandekerckhove K, Demeyer H, De Craemer M.   +6 more
europepmc   +1 more source